2024年10月至2025年2月，法国社区流感疫苗对发现感染的有效性。

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2025-02-01 DOI:10.2807/1560-7917.ES.2025.30.7.2500074

François Blanquart, Vincent Vieillefond, Benoit Visseaux, Claire Nour Abou Chakra, Marta C Nunes, Alexandra Jacques, Stephanie Haim-Boukobza, Laurence Josset, Valentin Wehrle, Guillaume Deleglise, Thomas Duret, Marie Anne Rameix-Welti, Bruno Lina, Vincent Enouf, Antonin Bal

{"title":"2024年10月至2025年2月，法国社区流感疫苗对发现感染的有效性。","authors":"François Blanquart, Vincent Vieillefond, Benoit Visseaux, Claire Nour Abou Chakra, Marta C Nunes, Alexandra Jacques, Stephanie Haim-Boukobza, Laurence Josset, Valentin Wehrle, Guillaume Deleglise, Thomas Duret, Marie Anne Rameix-Welti, Bruno Lina, Vincent Enouf, Antonin Bal","doi":"10.2807/1560-7917.ES.2025.30.7.2500074","DOIUrl":null,"url":null,"abstract":"Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 7","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843621/pdf/","citationCount":"0","resultStr":"{\"title\":\"Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.\",\"authors\":\"François Blanquart, Vincent Vieillefond, Benoit Visseaux, Claire Nour Abou Chakra, Marta C Nunes, Alexandra Jacques, Stephanie Haim-Boukobza, Laurence Josset, Valentin Wehrle, Guillaume Deleglise, Thomas Duret, Marie Anne Rameix-Welti, Bruno Lina, Vincent Enouf, Antonin Bal\",\"doi\":\"10.2807/1560-7917.ES.2025.30.7.2500074\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 7\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843621/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500074\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500074","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

自2024年11月以来，流感在欧洲高水平传播。使用基于2024年10月至2025年2月法国社区实验室数据的检测阴性研究，我们估计了疫苗对pcr检测流感感染的有效性（VE） (44,420/15,052；积极/消极的个人)。对于所有年龄组，总体VE为42% (95% CI: 37-46%)，其中甲型流感为26% (95% CI: 18-34%)，乙型流感为75% （95% CI: 66-82%）。≥65岁人群VE为22% (95% CI: 13-30%)， 0-64岁人群VE为60% （95% CI: 56-65%）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.